Healthcare / BiotechnologyKOSDAQ
$3315.00
-100.00 (-2.93%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $3.5B · quality 59.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$79.3B
P/E
24.4x
↑EV/EBITDA
8.5x
↓ROE
4.5%
↑Gross Margin
40.7%
↓Debt/Equity
0.53
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-9.2%
FCF CAGR
-37.6%
FCF margin
2.8%
FCF / Net income
1.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $123.77B · net income $3.24B · FCF $3.46B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $123.77B | $123.77B | $119.88B | $137.88B | $165.21B |
| Net Income | $3.24B | $3.24B | $-5.22B | $-15.59B | $4.70B |
| EBITDA | $11.83B | $11.83B | $3.44B | $-6.52B | $9.80B |
| EPS | 136.00 | 136.00 | -218.00 | -652.00 | 197.00 |
| Gross Margin | 40.7% | 40.7% | 41.4% | 31.2% | 33.0% |
| Operating Margin | 5.0% | 5.0% | -4.5% | -3.3% | 6.8% |
| Net Margin | 2.6% | 2.6% | -4.4% | -11.3% | 2.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.53 | 0.53 | 0.47 | 0.47 | 0.43 |
| Current Ratio | 1.62 | 1.62 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $3.46B | $3.46B | $2.26B | $5.73B | $14.26B |
| Returns | |||||
| ROE | 4.5% | 4.5% | -7.5% | -20.7% | 5.0% |
| Valuation | |||||
| P/E | 24.38 | 24.38 | — | — | 31.07 |
| EV/EBITDA | 8.54 | 8.54 | 51.29 | — | 16.54 |
| P/B | 1.09 | 1.09 | 2.34 | 3.16 | 1.56 |
| Growth & Yield | |||||
| Revenue Growth | 3.2% | 3.2% | -13.1% | -16.5% | — |
| EPS Growth | 162.4% | 162.4% | 66.6% | -431.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
29.3%
EPS terminal req.
$294.15
Spread vs growth
133.1%
5Y implied EPS CAGR
21.2%
EPS terminal req.
$355.92
Spread vs growth
141.2%
10Y implied EPS CAGR
15.5%
EPS terminal req.
$573.22
Spread vs growth
146.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-49.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-218.00 → 136.00
Residual
-49.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.